Leadership

THE TEAM

The Nonagen Therapeutics leadership team has a proven track record of successfully developing products and creating programs that result in improved patient outcomes and care.

 
IMG_3434circle2.png

Charles Joel Rosser, MD, MBA, FACS

Co-founder, President & CEO

Nonagen Therapeutics Corporation

Dr. Rosser obtained a BS degree in Biology from Fairleigh Dickinson University and an MD from Rutgers University School of Medicine (Robert Wood Johnson Medical School). Subsequently he performed his residency at Wake Forest University School of Medicine and fellowship at UT MD Anderson Cancer Center. He has previously held professorships at University of Florida, University of Central Florida and University of Hawaii. Currently, he is Professor at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center and CEO of Nonagen Bioscience Corp. Dr. Rosser has been PI of numerous clinical trials and has received extramural funding from American Cancer Society, Department of Defense and National Cancer Institute. In addition, he has authored over 200 peer reviewed research articles. His research interests include molecular diagnostics and experimental therapeutics.  Dr. Rosser has played a critical role in the development of N-803 (ALT-803), an IL15 analogue used in combination with BCG to treated bladder cancer, which has granted Breakthrough and Fast Track designation by the FDA.

 
SG.png

Steve Goodson, PhD

Vice President, Research and Development

Nonagen Therapeutics Corporation

Dr. Goodison obtained a BSc degree in Biochemistry from the University of Wales and a PhD in molecular biology from Oxford University in 1993 as a Wellcome Trust Scholar, and continued postdoctoral studies at Oxford University as a Wellcome Trust Fellow in the Dept. of Clinical Biochemistry. He has previously held professorships at University of California San Diego, University of Florida and University of Central Florida. He is currently Professor of Urology at the Mayo Clinic. Dr. Goodison has received several major NCI awards and published over 170 research articles. Research interests include tumor biology, gene regulation and translational studies in biomarker discovery for development of clinical diagnostic and prognostic assays.

 
DaveCircleCrop2.png

Dave Mori

Co-founder, Chief Development Officer

Nonagen Therapeutics Corporation

Dave Mori obtained a Bachelor of Commerce Degree in Entrepreneurial Management from Royal Roads University in British Columbia, Canada. Dave has over 20 years of experience operating and advising businesses in North America and Asia. Dave has had a lifelong interest and passion towards helping organizations that prevent and cure cancer. As CDO, Dave is responsible for guiding Nonagen leadership in all matters relating to marketing, sales and fundraising.